ZA948631B - 5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds - Google Patents

5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds

Info

Publication number
ZA948631B
ZA948631B ZA948631A ZA948631A ZA948631B ZA 948631 B ZA948631 B ZA 948631B ZA 948631 A ZA948631 A ZA 948631A ZA 948631 A ZA948631 A ZA 948631A ZA 948631 B ZA948631 B ZA 948631B
Authority
ZA
South Africa
Prior art keywords
arylisoxazol
substituted
carboxylic acid
acid compounds
amino carboxylic
Prior art date
Application number
ZA948631A
Other languages
English (en)
Inventor
Klaus Peter Bogeso
Povi Krogsgaard-Larsen
Sibylle Moltzen Lenz
Erik Falch
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of ZA948631B publication Critical patent/ZA948631B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA948631A 1993-11-03 1994-11-02 5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds ZA948631B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK931243A DK124393D0 (da) 1993-11-03 1993-11-03 Compounds

Publications (1)

Publication Number Publication Date
ZA948631B true ZA948631B (en) 1995-07-10

Family

ID=8102626

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA948631A ZA948631B (en) 1993-11-03 1994-11-02 5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds

Country Status (17)

Country Link
EP (2) EP0994107A1 (cs)
JP (1) JPH09504531A (cs)
KR (1) KR960705797A (cs)
CN (1) CN1056837C (cs)
AU (1) AU680062B2 (cs)
CA (1) CA2175685A1 (cs)
CZ (1) CZ127296A3 (cs)
DK (1) DK124393D0 (cs)
FI (1) FI961872A (cs)
HU (1) HUT74692A (cs)
NO (1) NO306159B1 (cs)
NZ (1) NZ275088A (cs)
PL (1) PL314182A1 (cs)
RU (1) RU2138488C1 (cs)
SK (1) SK56496A3 (cs)
WO (1) WO1995012587A1 (cs)
ZA (1) ZA948631B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025405A1 (en) * 1995-02-13 1996-08-22 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
UA52698C2 (uk) * 1996-10-04 2003-01-15 Х. Луннбек А/С Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі
IT1318636B1 (it) * 2000-07-21 2003-08-27 Roberto Pellicciari Derivati dell'acido 2- o 3- tenoico ad attivita' antagonista deirecettori del glutammato.
UA78529C2 (en) * 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
CA2521313A1 (en) 2003-04-09 2004-10-28 Wyeth Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.o)non-1(7)-3n-2-yl)-al kyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
TW200514775A (en) 2003-10-22 2005-05-01 Wyeth Corp Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
PL2076502T3 (pl) 2006-06-08 2011-09-30 Lilly Co Eli Podstawione karboksyamidy jako antagoniści receptorów metabotropowych grupy I

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69102816T2 (de) * 1990-05-11 1995-03-16 Sankyo Co Piperdinyloxy- und Chinindidinyloxy- isoxazol- Derivate, ihre Herstellung und ihre therapeutische Verwendung.
ES2133416T3 (es) * 1992-10-23 1999-09-16 Merck Sharp & Dohme Ligandos de subtipos de receptores de dopamina.

Also Published As

Publication number Publication date
EP0994107A1 (en) 2000-04-19
RU2138488C1 (ru) 1999-09-27
NO306159B1 (no) 1999-09-27
DK124393D0 (da) 1993-11-03
AU8057994A (en) 1995-05-23
CN1056837C (zh) 2000-09-27
AU680062B2 (en) 1997-07-17
NZ275088A (en) 1997-08-22
PL314182A1 (en) 1996-09-02
CZ127296A3 (en) 1996-09-11
CN1136810A (zh) 1996-11-27
SK56496A3 (en) 1996-12-04
JPH09504531A (ja) 1997-05-06
NO961783L (no) 1996-06-25
WO1995012587A1 (en) 1995-05-11
CA2175685A1 (en) 1995-05-11
EP0726896A1 (en) 1996-08-21
HUT74692A (en) 1997-01-28
NO961783D0 (no) 1996-05-02
FI961872A0 (fi) 1996-05-02
FI961872A (fi) 1996-05-03
HU9601167D0 (en) 1996-07-29
KR960705797A (ko) 1996-11-08

Similar Documents

Publication Publication Date Title
AU4893993A (en) Carboxylic acid derivatives
AU5230693A (en) Carboxylic acid derivatives
HU9401917D0 (en) Propionic acid derivatives
GB9325558D0 (en) Percaboxylic acids
HU9400143D0 (en) Quinolon-and naphtiridon-carboxylic acid derivatives
EP0645391A3 (en) Aminobenzoic acid derivatives.
AU1246995A (en) Alpha-quaternary-alpha-amino acids for use as cns agents
SG54218A1 (en) 2-keto-3-methyl-4-hydroxy-valeric acid
HU9202817D0 (en) Bicyclical carboxylic acid derivatives
IL129135A0 (en) 3-Alkoxyisoxazol-4- YL-substituted 2-amino carboxylic acid compounds
ZA938988B (en) Substituted benzoic acids
HU9403116D0 (en) Epoxy-succinic acid derivatives
HU9600322D0 (en) Novel quinolone carboxylic acid derivatives
ZA911398B (en) Carboxylic acid derivatives
HU9601167D0 (en) 5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds
HU9503309D0 (en) Carboxylic acid amide benzothiophene-s-oxides
ZA913132B (en) Carboxylic acid derivatives
ZA941668B (en) Acyloxyhexanoic acid derivatives
HUP9802329A3 (en) Carboxylic acid derivatives
ZW7994A1 (en) 2-oximino-2-thienyl-acetic acid derivatives
ZA941923B (en) Phenoxyphenylacetic acid derivatives
SI0934286T1 (en) 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds
GB9312769D0 (en) Ricinoleic acid derivatives
GB9325620D0 (en) Carboxylic acid derivatives
GB9306448D0 (en) Carboxylic acid derivatives